

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Neurology</b>				
Neurology	Glycogen synthase kinase 3 $\beta$ (GSK3B)	<i>In vitro</i> and mouse studies suggest that manzamine derivatives could help treat brain infections and other neurological diseases. Docking studies showed that 8-hydroxymanzamine A bound to the noncompetitive ATP-binding pocket of GSK3B, a potential target in neurodegenerative diseases such as depression and Parkinson's disease (PD). <i>In vitro</i> , manzamine A permeated the blood brain barrier (BBB), suggesting that derivatives could be used to treat cerebral infections or neurological diseases. Next steps include additional biosynthesis procedures to reduce off-target drug-DNA interactions without impairing kinase inhibition. Neurim Pharmaceuticals Ltd. is developing Neu-120, a GSK3B inhibitor that is in Phase II testing to treat PD.	Findings patented by The University of Mississippi for control of infectious diseases; joint patent with Midwestern University pending for neuroinflammatory indications; licensed to undisclosed parties for infectious diseases; available for licensing for neuroinflammation	Peng, J. <i>et al. J. Med. Chem.</i> ; published online Dec. 17, 2009; doi:10.1021/jm900672t <b>Contact:</b> Mark T. Hamann, Bristol-Myers Squibb Co., Wallingford, Conn. e-mail: <a href="mailto:mthamann@olemiss.edu">mthamann@olemiss.edu</a>
<p><i>SciBX</i> 3(3); doi:10.1038/scibx.2010.95 Published online Jan. 21, 2010</p>				